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Composite scaffolds for the engineering of hollow organs and
tissues
Abstract
Several types of synthetic and naturally derived biomaterials have been used for augmenting hollow
organs and tissues. However, each has desirable traits which were exclusive of the other. We fabricated
a composite scaffold and tested its potential for the engineering of hollow organs in a bladder tissue
model. The composite scaffolds were configured to accommodate a large number of cells on one side
and were designed to serve as a barrier on the opposite side. The scaffolds were fabricated by bonding a
collagen matrix to PGA polymers with threaded collagen fiber stitches. Urothelial and bladder smooth
muscle cells were seeded on the composite scaffolds, and implanted in mice for up to 4 weeks and
analyzed. Both cell types readily attached and proliferated on the scaffolds and formed bladder
tissue-like structures in vivo. These structures consisted of a luminal urothelial layer, a collagen rich
compartment and a peripheral smooth muscle layer. Biomechanical studies demonstrated that the tissues
were readily elastic while maintaining their pre-configured structures. This study demonstrates that a
composite scaffold can be fabricated with two completely different polymer systems for the engineering
of hollow organs. The composite scaffolds are biocompatible, possess adequate physical and structural
characteristics for bladder tissue engineering, and are able to form tissues in vivo. This scaffold system
may be useful in patients requiring hollow organ replacement.
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Abstract:   
Several types of synthetic and naturally derived biomaterials have been used for 
augmenting hollow organs and tissues. However, each has desirable traits which were 
exclusive of the other. We fabricated a composite scaffold and tested its potential for the 
engineering of hollow organs in a bladder tissue model. The composite scaffolds were 
configured to accommodate a large number of cells on one side and were designed to 
serve as a barrier on the opposite side. The scaffolds were fabricated by bonding a 
collagen matrix to PGA polymers with threaded collagen fiber stitches. Urothelial and 
bladder smooth muscle cells were seeded on the composite scaffolds, and implanted in 
mice for up to 4 weeks and analyzed. Both cell types readily attached and proliferated 
on the scaffolds and formed bladder tissue-like structures in vivo. These structures 
consisted of a luminal urothelial layer, a collagen rich compartment and a peripheral 
smooth muscle layer. Biomechanical studies demonstrated that the tissues were readily 
elastic while maintaining their pre-configured structures. This study demonstrates that a 
composite scaffold can be fabricated with two completely different polymer systems for 
the engineering of hollow organs. The composite scaffolds are biocompatible, possess 
adequate physical and structural characteristics for bladder tissue engineering, and are 
able to form tissues in vivo. This scaffold system may be useful in patients requiring 
hollow organ replacement.  
 
Keywords:  Composite scaffolds, PGA, Acellular Bladder Matrix, hollow organs, 
bladder 
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INTRODUCTION 
Biomaterials for tissue engineering provide a three-dimensional environment that allows 
cells to develop new tissues with appropriate structure and function (1). These materials 
are usually designed to replicate the biologic and physical function of the native extra 
cellular matrix (ECM) found in the body to enhance tissue formation. Thus, an ideal 
biomaterial should be biocompatible and support tissue growth without inducing severe 
inflammatory processes (2) that lead to foreign-body giant cell formation or fibrous 
scarring. In addition, the biomaterial should provide adequate structural support to the 
neo-organ during tissue development and degrade gradually over time as cells undergo 
spatial organization. This is especially important for the engineering of hollow organs 
such as blood vessels, esophagus and bladders, where biomaterials serve as a 
separator that interfaces with the content of the cavity and the viscera. Therefore, 
biomaterials which constitute a scaffolding system for these organs should serve as a 
barrier while accommodating sufficient amounts of cells that facilitate tissue 
development.  
 
Traditionally, two main classes of biomaterials have been utilized for the engineering of 
hollow organs; acellular matrices derived from donor tissues (3-8), (e.g., bladder 
submucosa (lamina propria) and small intestinal submucosa), and synthetic polymers 
such as polyglycolic acid (PGA) (9, 10), polylactic acid (PLA), and poly(lactic-co-glycolic 
acid) (PLGA). These materials have been tested in respect to their biocompatibility in 
the host tissues (11, 12). Each type of biomaterials has desirable traits which are 
exclusive of the other. Acellular tissue matrices possess the desired biocompatibility(11-
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13), contain biomimetic factors(14-16) that promote tissue development and have 
adhesion domain sequences (e.g., RGD) that may assist in retaining the phenotype and 
activity of many types of cells (17). These matrices are known to slowly degrade upon 
implantation and are usually replaced and remodeled by ECM proteins synthesized and 
secreted by transplanted or ingrowing cells (18-25). In contrast, synthetic polymers can 
be manufactured reproducibly on a large scale with controlled properties of their 
strength, degradation rate and ultrastructure (26, 27). Both classes of biomaterials have 
been used either with or without cells for the tissue engineering of hollow organs and 
tissues, including the bladder (5, 6, 10), urethra (3, 4, 9), ureter (7), esophagus (8, 28), 
intestine (28), uterus (29), vagina (29, 30) and blood vessels (31, 32). 
 
Most hollow organs are organized in a similar fashion, consisting of epithelium or 
endothelium on the lumen surrounded by a collagen rich connective tissue and muscle 
layer. Epithelial or endothelial layer serves as a barrier that prevents the content of the 
lumen from permeating into the body cavity. The collagen rich layer and muscle tissue 
surrounding the epithelium/endothelium maintain the structural integrity of the organ. 
The cells composing these layers interact with each other and other proteins to regulate 
cellular differentiation and function (14, 33). Thus, an ideal biomaterial must provide an 
environment in which corresponding cell types could interact with each other to guide 
appropriate regulation that governs adhesion, proliferation, migration, and differentiation 
can occur.  Therefore, multiple cell types are required to create a hollow organ with the 
appropriate “layered” structure. Since each of these cell types favors different conditions 
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for optimal growth and differentiation, ideal tissue engineering strategies must take 
these factors into account.  
Biomaterials for hollow organs should provide structural support for distinct cell layers, 
including an adequate surface for stable attachment of epithelial/endothelial cells. It 
should also provide adequate biomechanical support to harbor a high density of smooth 
muscle cells on the exterior surface without collapsing prematurely. The development of 
specialized biomaterials consisting of these components might improve current tissue 
engineering techniques.  Herein, we designed and fabricated a novel composite scaffold 
that utilizes both the acellular tissue matrix and synthetic polymers. This scaffold system 
was created by bonding the two heterogeneous materials together with threaded 
collagen fiber stitches to form a dual layered structure. Specifically, the acellular tissue 
matrix serves as a barrier that would prevent the luminal content from permeating to the 
viscera while providing optimal surface for epithelial cell adherence. The synthetic 
polymer layer with large pores is designed to accommodate sufficient numbers of 
muscle cells and maintain structural integrity of the scaffold at the same time. In this 
study we examined the validity of composite scaffolds using a bladder tissue model for 
their possible utility in engineering of other hollow organs. 
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DESCRIPTION OF METHODS 
 Preparation of composite biomaterial 
Composite scaffold was created by using 2 different materials: acellular bladder matrix 
(ABM) and poly glycolic acid (PGA, U.S. Surgical Corp. Norwalk, CT, USA). Both 
materials have been shown to be biocompatible and safely used clinically (11, 12, 34, 
35). Acellular tissue matrix, obtained from porcine bladders, was processed using a 
multiple-step detergent wash protocol developed in our laboratory (12, 16). Each 
porcine bladder was rinsed with running tap water, and placed in a -20OC freezer 
overnight. The bladder was thawed in cool water, opened with sharp scissors, and 
placed flat on a table. The muscle layer was micro-dissected and removed with sharp 
scissors while the epithelial cell layer was removed by mechanically scraping the 
epithelium with a No. 10 surgical blade. The remaining tissue, consisting mainly of 
lamina propria, was placed in a container filled with 0.9% normal saline followed by 
continued agitation on an elliptical shaker at 4OC. The acellular matrix was treated with 
distilled water for 2 days to lyse the cells residing within the tissue. Distilled water was 
changed twice each day. Subsequently, the tissues were treated with 1% Triton X100 
and 0.1% ammonium hydroxide in a stirring flask at 4OC for 7 days. The detergent was 
exchanged daily. Subsequently, the bladder matrix was rinsed with distilled water at 
4OC for two days followed by a treatment with phosphate buffered saline (PBS) for 24 
hours. Small matrix samples were cut and analyzed by hematoxylin and eosin. A 
second round of detergent wash procedure was used if the matrices were not entirely 
free of cellular content. The bladder matrix was trimmed to the desired size and stored 
frozen at -80 OC until needed.  
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 To bond the ABM to the PGA, we initially used a heat bonding technique at 200oC for 
80 minutes, followed by lyophilization and sterilization. However, the heat and 
lyophilization denatured the collagen which may have influenced the biologically active 
molecules associated with the matrix (16). Therefore, we decided to keep the 
biomaterial in liquid (36) during the process and use a physical stitching method 
instead. 
The ABM was placed on a pre-configured PGA non-woven felt (60mg/cc, 123 denier 56 
filament, U.S. Surgical Corp. Norwalk, CT, USA) and stretched uniformly until the 
dimension remained reasonably constant. A light scrim of PGA was placed on the 
lumen side (top) of the collagen. This scrim was composed of a one layer PGA mesh 
and is used to prevent the locking fiber from cutting through the ABM. This ensures that 
both materials are stably stitched together. The entire structure was held together by the 
frictional grip of these fibers locking the collagen matrix into the system. The composite 
structure was then fed into a Hunter 11" Needle loom tacker (Hunter Inc., Reston, VA). 
The loom tacker passed barbed needles through the composite structure, pulling 
individual filaments through in the "Z" direction. The composite was then turned over 
and passed through the needle loom a second time to strengthen the bonding. During 
manufacturing of the composite scaffold, care was taken to maintain the correct 
orientation of the ABM layer. The final composite biomaterial consisted of a two layered 
structure with a thick PGA layer on one side and an ABM layer on the other. This 
biomaterial has excellent surgical handling qualities, is highly flexible and can be 
sutured easily. 
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SEM and biomechanical testing was performed on every batch of the materials prior to 
in vivo use and these tests showed stable bonding with a high reproducibility. The 
material was stored at -20 OC until use. 
 
Cell cultivation and seeding 
We used primary cells harvested from canine bladders using established protocols (10, 
37-39). Bladder tissue was microdissected, and the mucosal and muscular layers were 
separated. Approximately 1x1 cm sized mucosal tissue with the urothelial side facing up 
into a 10 cm culture dish. The mucosal surface was gently scraped with a No. 10 
scalpel under sterile conditions. The detached cell clusters were confirmed using phase 
microscopy and placed in serum-free keratinocyte growth medium (Keratinocyte SFM, 
Gibco, Grand Island, NY) containing 5 ng/mL epidermal growth factor and 50 cLg/mL 
bovine pituitary extract.  
The muscle layer was cut in small tissue fragments of 1x1 mm and placed onto a dry 
10cm culture dish. After 10 minutes, Dulbecco’s Modified Eagle’s Medium (DMEM; 
Gibco, Grand Island, NY) supplemented with 10% fetal calf serum was carefully added. 
The cells were incubated at 37°C in a humidified atmosphere containing 5% CO2.  Both 
urothelial and smooth muscle cells were expanded separately until desired cell numbers 
were obtained. In these experiments, cells less than passage 5 were used for seeding.  
 
The biomaterial was cut into 1 x1 cm pieces and placed in 70% alcohol for 6 hours in 
order to minimize potential bacterial contaminants. No permanent sterilization was used 
in this study. The expanded urothelial and smooth muscle cells were trypsinized, 
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washed, and collected as a pellet. Urothelial cells were seeded onto the ABM surface of 
the composite biomaterial at a concentration of 1 x 107 cells per cm2 and the construct 
was then incubated in serum-free keratinocyte growth medium for 2 days. 
Subsequently, the biomaterial was turned over and smooth muscle cells were seeded 
onto the PGA side of the construct at a concentration of 2 x 107 cells per cm2. The 
seeded constructs were then placed in DMEM supplemented with 10% fetal calf serum 
for an additional 2 days before implantation. Controls consisting of PGA only or ABM 
only were seeded following the same protocol. 
 
 
Scanning Electron Microscopy (SEM) 
For ultrastructural analysis, composite biomaterials were fixed in a 2.5% glutaraldehyde 
solution containing 0.085M cacodylate buffer for 1 hour. All samples were dehydrated 
through a graded series of ethanol and were eventually stored at 4O C. After critical 
point drying, samples of material were sputter-coated with (Hommur V) gold and 
platinum and analyzed using a scanning electron microscope (SEM, Leo 1450 VP) at 
various magnifications. 
SEM confirmed the bonding of the 2 biomaterials (Figure 1). A thick collagen layer was 
formed by the ABM. The penetrating fibers used to bond the two biomaterials together 
were clearly visible on the SEM images. The non-woven PGA on the opposite side was 
porous.  
 
Biomechanical Testing 
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Rectangular tissue strips measuring 30 mm x 10 mm were used (n=5 per group) for 
biomechanical testing. The biomaterials were placed in PBS for 4 hours prior to testing. 
Tensile tests (Instron model 5544, MA, USA) were performed by elongating the tissue 
strips longitudinally at a speed of 0.05 mm/second with a preload of 0.2 N until failure. 
The grip-to-grip spacing was approximately 20 mm. All specimens were tested at room 
temperature and kept moist. The maximum tensile strength (N/cm) and strain forces 
(MPa), were determined and analyzed. Further, the Young’s modulus was calculated to 
evaluate the stiffness and elasticity of the biomaterial. Native bladder wall served as a 
normal control. 
The results showed that the composite biomaterial has favorable biomechanical 
characteristics that are comparable to those of native bladder tissue (Figure 2). Five 
samples were measured in each group. The tensile strain at failure was 1.1 ± 0.1 
mm/mm for the composite and 1.3± 0.2 mm/mm for native bladder. This difference was 
not significant. The tensile stress at break was 1.5 ± 0.4 MPa for the composite 
biomaterial and 0.77± 0.2 MPa for native bladder (p=0.006). The load at break was 35.8 
± 7.1 N for the composite biomaterial and 18.5± 3.2 N for native bladder (p=0.003). The 
calculated Young’s modulus was 0.0020 ± 0.0005 for the composite biomaterial and 
0.0011 ± 0.0003 for native bladder (p=0.008). The statistical differences in the 
biomechanical tests do not reflect true biological differences, but rather indicate narrow 
standard deviations due to successful standardization of this delicate process. Since 
bioabsorbable materials were used in this study a slightly stronger composite is 
desirable. The degradation of the biomaterials will weaken the material over time until 
the host begins to support the construct by newly synthesized collagen fibers. 
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Porosity assessment  
Most hollow organs require a water tight repair. In esophageal, gastric, intestinal and 
bladder engineering, leakage from the biomaterial leads to early inflammation and 
infection which may result in the death of the patient. Therefore, the porosity of the 
biomaterials was assessed before seeding with cells, after cell seeding, and after 14 
and 28 days in vivo. We used the flow through method (40) which defines porosity as 
the flow of water through the biomaterial per unit time and per unit surface area at a 
defined pressure.  
For this test the biomaterial was clamped between two flat metal plates with central 
holes of 0.5cm2 surface area. Flexible tubing was connected to one side of the metal 
plate applying static water pressure. The static pressure head was defined by the 
difference in height between the water level and the specimen. Biomaterials were 
placed in the apparatus and subjected to the static pressure for one minute and leakage 
flow was collected in a graduated cylinder for quantification of volume. The flow through 
porosity was defined as the amount of water flowing through one square centimeter of 
construct, measured in milliliters per minute, at a pressure of 120 mmHg. All specimens 
were tested at room temperature and kept moist.  
The unseeded composite biomaterial had a porosity of 506.2 ± 7.1 ml/min/cm2 while the 
PGA-only control had a porosity of 714.8 ± 7.7 ml/min/cm2. After cell seeding, the 
porosity declined to 481.6 ± 28.4 ml/min/cm2 for the composite biomaterial and to 634.5 
± 18.8 ml/min/cm2 for the PGA-only control. The differences between all groups were 
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significant (p>0.05). The ABM-only control and all samples retrieved from in vivo 
experiments at 2 and 4 weeks were 100% water tight. The process of sewing the 
constructs together resulted in numerous needle induced holes into the ABM layer, thus 
increasing the porosity and flow. This indicates that in vivo cell proliferation and tissue 
formation is needed to achieve the ultimate goal of water tightness. Although the 
porosity index presented is a widely used method of comparing different biomaterials, it 
may not predict whether or not the composite biomaterial will leak in vivo. 
 
 
In Vivo Evaluation  
All procedures were performed in accordance with the institution’s Animal Care and Use 
Committee. Twenty-four athymic mice (nu/nu, Charles River Laboratories Inc. 
Wilmington, MA, USA) were randomly assigned to 3 groups. Group 1 received the 
seeded composite biomaterial (n=16), while Group 2 and 3 served as controls and 
received seeded PGA constructs (n=16) and seeded ABM constructs (n=16) 
respectively.  
All surgeries were performed under general anaesthesia (2% isoflurane). The area of 
surgery was disinfected with iodine solution. A 3 cm long incision was made on the 
dorsum of each mouse. In all groups, two seeded constructs were placed 
subcutaneously between the muscle and skin. The surgical wound was closed using 
absorbable running sutures. All animals survived the surgical procedure without 
noticeable complications. During the first 24 hours, the mice received routine analgesia 
with buprenorphine (0.1 mg/kg) 2 times per day. Animals were housed together, allowed 
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free access to food and water, and were maintained on a light-dark cycle of 12 hours 
each. 
Four animals from each group were sacrificed on day 14 and day 28 after implantation.  
At the time of sacrifice, the animals were euthanized by CO2 followed by cervical 
dislocation. Immediately after euthanasia, the implant site was inspected and the 
engineerd tissue retrieved. The retrieved constructs and the surrounding tissues were 
inspected grossly and histologically. Macroscopically, there was no evidence of infection 
or fibrosis, and the biomaterial was integrated into surrounding connective tissue. All 
samples showed signs of neo-vacularization (Figure 3). Seeded ABM-only grafts were 
not able to form voluminous tissue and remained as a thin layer. PGA and the 
composite biomaterial both showed the formation of voluminous tissue (Figure 3). The 
formation of voluminous tissue is indicative of cell proliferation within the constructs. 
This is only possible if the cells are provided with sufficient nutrients and oxygen. At 2 
weeks, the volume of tissue resulting from seeded ABM, composite biomaterial and 
PGA were 36.1± 4.4 mm3, 99.7± 18.0 mm3   and 124.6± 8.5 mm3 (p< 0.014), 
respectively. All seeded constructs showed some reduction in volume at 4 weeks with 
22.9± 7.6 mm3., 79.1± 11.0 mm3 and 104.3± 16.0 mm3 for seeded ABM, composite 
biomaterial and PGA (p< 0.003), respectively. Our results indicate a slight reduction in 
volume of the composite and the controls at 4 weeks. This might be due to the 
degradation of the PGA fiber loops, which starts at the interface to host tissue, making 
the retrieved sample appear smaller. 
 
Histological Analysis  
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For histological analysis, engineered bladder tissues were washed in PBS and 
embedded in tissue freezing medium (OCT compound; Miles, Elkhart, NJ). 
Cryosections of 6 µm thickness (Leica RM 2145) were analyzed with hematoxylin and 
eosin, Masson's trichrome and immunocytochemistry using cell specific antibodies. 
Urothelial cells were identified by probing tissue sections with polyclonal anti-
pancytokeratins AE1/AE3 (Dako, Carpinteria, CA, Cat# M3515, Lot# 005500, 1:50), 
while smooth muscles were identified using anti-alpha-actin (Santa Cruz, Santa Crz, 
CA, Cat# sc-32251,  Lot# E0806, 1:20). As secondary antibodies, we used biotinylated 
horse anti-mouse antibody (Vector Laboratories, Burlingame, CA, Cat# BA 2000, Lot# 
R0719, 1:300). Detection was performed with the VectaStain ABC avidin-biotin 
detection kit (Vector Laboratories, Burlingame, CA) and visualized with the DAB 
chromogen. Tissue sections that were not incubated with primary antibody were used 
as negative controls.  
 Hematoxylin and Eosin staining of all samples showed high cellularity and good tissue 
organization, suggesting that new tissue was formed in vivo (Figure 4). All materials 
showed excellent biocompatibility. There was a minimal mixed cellular infiltration that 
was devoid of lymphoid follicles or calcifications in all cases. The seeded ABM-only 
control samples showed both cell types attached to the thin biomaterial. However, a 
thick muscular compartment was absent. Seeded PGA-only control constructs showed 
both cell types and a developed smooth muscle layer, but the interface between 
urothelial cells and smooth muscle cells was less distinct, with urothelial cells 
penetrating deep into the muscle layer. Only the composite biomaterial was able to 
maintain the specific organization of normal bladder tissue. The histological analysis 
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revealed a distinct 3 layer architecture with a urothelial layer followed by a dense 
collagen layer followed by a thick muscle compartment (Figure 4A). The urothelial layer 
was several cell layers thick, with smaller cells close to the basement membrane and 
larger cells 4-5 cell layers away.  In addition, the seeded smooth muscle cells had 
begun to align and form compact muscle bundles. Immunohistochemistry confirmed the 
phenotype of the urothelial and smooth muscle cells.  
 
Western blot analysis 
Western blot analysis for anti-pancytokeratins AE1/AE3, anti-desmin (BD Biosciences, 
San Jose, CA, 1:50) and anti-alpha-actin was performed on protein isolated from 
retrieved tissue specimens (n=4). To minimize contamination from host myo-fibroblasts 
we have used only the center sections of the retrieved constructs for analysis. Implanted 
composite constructs without cells were prepared in the same manner and these extracts were 
used as controls for the Western blotting assays. Protein samples were prepared using 
routine extraction methods. The specimens were rapidly homogenized in standard lysis 
buffer (Tris-20 1M, NaCl 3M, Triton 10% with protease inhibitor) and incubated in the 
buffer on ice. After 30 minutes on ice, the lysates were centrifuged at 12,500 x g for 15 
minutes and the supernatants were kept. The protein concentration in each supernatant 
was determined using the Bio-Rad DC Protein Assay Kit (Bio-Rad,. Hercules, CA). 
Aliquots of 20 µg total protein were then separated via SDS-PAGE (12% gel; 120 V and 
200 mA). The proteins were transferred to nitrocellulose membranes.  After transfer, the 
membranes were blocked with 5% bovine serum albumin (BSA). The blots were probed 
with the primary antibodies overnight at 4OC, washed, and subsequently treated with 
secondary antibody conjugates for 1 hour at room temperature. Immunoblots were 
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treated with an enzyme-linked chemiluminescence reagent (Western Lightning Plus , 
Perkin Elmer, Boston, MA) and exposed to X-ray film for 30 seconds to 5 minutes. 
Samples retrieved at 4 weeks after implantation showed the presence of pancytoceratin 
AE1/AE3, actin and desmin, indicating that urothelial and smooth muscle cells had 
developed in the implants.  Control composite biomaterial implanted in vivo for 4 weeks 
without prior cell seeding remained negative for these markers.   
 
Statistical analysis: 
In this report all data were expressed as averages and standard deviations, and these 
were analyzed using unpaired t-tests (porosity test and mechanical studies) with 
statistical software (SPSS v11; SPSS Inc, Chicago, IL). A p-value of less than 0.05 was 
considered significant. The tissue volumes were analyzed by one-way ANOVA. If 
significant, the groups were further analyzed by Bonferroni post-hoc testing. An alpha of 
p>0.05 was considered significant.   
 
 
 
Concluding Remarks 
Scaffold designing for hollow organs requires a special consideration as the 
biomaterials constituting a scaffolding system should serve as a barrier between the 
cavity and the viscera while accommodating sufficient amounts of cells that facilitate 
tissue development. In this article we configured a composite scaffolding system by 
bonding a collagen matrix to PGA polymers with threaded collagen fiber stitches. This 
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scaffolding system accommodates a large number of cells on one side and serves as a 
barrier on the other side. We show that the composite scaffolds made from ABM and 
PGA remain biocompatible, possess ideal physical and structural characteristics for 
hollow organ applications, and are able to form tissues in vivo. This scaffold system 
may be useful in the future in patients requiring hollow organ and tissue replacement. 
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Legends  
 
Figure 1. Ultra structural analysis   
A,B) Scanning electron microscopy. The composite scaffolds, consisting of a naturally-
derived collagen-based acellular matrix and polyglycolic acid polymers, are bonded 
after fabrication, and maintained their ultrastructural properties. Scale bar represents 
2mm (A) and 500µm (B) 
C) Porosity assessment by the flow-through method. The unseeded composite 
biomaterial shows a porosity of 506.2 ± 7.1 ml/min/cm2 while the PGA-only control 
demonstrates a porosity of 714.8 ± 7.7 ml/min/cm2. The relatively high flow-through 
porosity of the composite biomaterial is likely due to the bonding technique used, which 
punches hundreds of tiny holes into the ABM for suturing. After cell seeding, the 
porosity is reduced to 481.6 ± 28.4 ml/min/cm2 for the composite biomaterial and to 
634.5 ± 18.8 ml/min/cm2 for the PGA-only control. All retrieved constructs at 2 and 4 
weeks were water tight. The differences between all groups were significant (p>0.05).  
 
Figure 2. Biomechanical Analysis. 
The mechanical analysis shows that composite biomaterial has favorable biomechanical 
characteristics which are comparable to native bladder. A) The tensile strain at break 
was 1.1 ± 0.1 mm/mm for the composite and 1.3± 0.2 mm/mm for native bladder (not 
significant). B) The tensile stress at break was 1.5 ± 0.4 Mpa for the composite 
biomaterial and 0.77± 0.2 Mpa for native bladder (p=0.006). C) The load at break was 
35.8 ± 7.1 N for the composite biomaterial and 18.5± 3.2 N for native bladder (p=0.003). 
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D) The calculated Young’s modulus was 0.0020 ± 0.0005 for the composite biomaterial 
and 0.0011 ± 0.0003 for native bladder (p=0.008). 
 
Figure 3. Gross Evaluation  
 A-C) Cell seeded scaffolds at retrieval. Seeded ABM-only (A) grafts were not able to 
form bulky tissue and remained as a thin layer. Composite biomaterial (B) and PGA (C) 
both showed the formation of bulky tissue. 
D) Volume assessment at 2 and 4 weeks. At 2 weeks the volumes for seeded ABM, 
composite biomaterial and PGA were 36.1± 4.4 mm3 , 99.7± 18.0 mm3   and 124.6± 8.5 
mm3. The groups were all significantly different (p< 0.014). All seeded constructs 
showed some reduction in volume at 4 weeks with 22.9± 7.6 mm3., 79.1± 11.0 mm3 and 
104.3± 16.0 mm3 for seeded ABM, composite biomaterial and PGA. The groups were all 
significantly different (p< 0.003). Error bars represent Standard Error of the Mean 
(SEM). 
 
Figure 4: Histology and Western Blot Analysis 
A) Histology of cell seeded composite scaffolds 4 weeks after implantation showed 
characteristics of native bladder tissue: urothelial (U) and smooth muscle cell (SM) 
layers. The collagen layer (C) formed a structure similar to the basement membrane 
and the lamina propria. Due to the differences in stiffness of the 2 materials used the 
sectioning was technically demanding. The asterisk indicates a rupture of the composite 
biomaterial due to shear forces during sectioning.  Hematoxylin and Eosin stain, 50x, 
Scale bar represents 100 µm. B) Urothelial cells seeded onto the collagen (C) surface of 
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the composite biomaterial for a mature urothelial layer. Hematoxylin and Eosin stain 
200x, Scale bar represents 50 µm. C) Imunohistochemistry confirming the urothelial 
phenotype (anti-pancytceratine AE1/AE3), 200x, Scale bar represents 50 µm. D) The 
seeded smooth muscle cells started to organize in an aligned fashion and form compact 
muscle bundles within the PGA part of the composite biomaterial. Hematoxylin and 
Eosin stain 200x, Scale bar represents 50 µm. E) Immunohistochemistry was able to 
confirm the smooth muscle phenotype (anti-actin). 200x, Scale bar represents 50 µm. F) 
The trichrome stain again reveled the distinct 3 layer architecture with a urothelial layer 
followed by a dense collagen layer (blue) followed by a thick muscle compartment. The 
asterisk indicates a rupture of the composite biomaterial due to shear forces during 
sectioning. 20x, Scale bar represents 500 µm.  
G) Western blot analyses using anti-alpha-actin, anti-desmin and anti-pancytokeratins 
AE1/AE3 demonstrate the presence of protein expression characteristic for urothelial 
cells and smooth muscle cells within the cell seeded matrices. 
 
 
 
 
  
 
References: 
1. Atala, A. (2003) Clin Plast Surg 30, 649-67. 
2. Atala, A. (2008) Pediatr Res. 
 20
3. Kropp, B. P., Ludlow, J. K., Spicer, D., Rippy, M. K., Badylak, S. F., Adams, M. C., 
Keating, M. A., Rink, R. C., Birhle, R., and Thor, K. B. (1998) Urology 52, 138-42. 
4. Chen, F., Yoo, J. J., and Atala, A. (1999) Urology 54, 407-10. 
5. Yoo, J. J., Meng, J., Oberpenning, F., and Atala, A. (1998) Urology 51, 221-5. 
6. Kropp, B. P., Rippy, M. K., Badylak, S. F., Adams, M. C., Keating, M. A., Rink, R. C., 
and Thor, K. B. (1996) J Urol 155, 2098-104. 
7. Shokeir, A., Osman, Y., El-Sherbiny, M., Gabr, M., Mohsen, T., and El-Baz, M. (2003) 
Eur Urol 44, 603-9. 
8. Urita, Y., Komuro, H., Chen, G., Shinya, M., Kaneko, S., Kaneko, M., and Ushida, T. 
(2007) Pediatr Surg Int 23, 21-6. 
9. Olsen, L., Bowald, S., Busch, C., Carlsten, J., and Eriksson, I. (1992) Scand J Urol 
Nephrol 26, 323-6. 
10. Oberpenning, F., Meng, J., Yoo, J. J., and Atala, A. (1999) Nat Biotechnol 17, 149-55. 
11. Pariente, J. L., Kim, B. S., and Atala, A. (2001) J Biomed Mater Res 55, 33-9. 
12. Pariente, J. L., Kim, B. S., and Atala, A. (2002) J Urol 167, 1867-71. 
13. Eberli, D., Susaeta, R., Yoo, J. J., and Atala, A. (2007) Int J Impot Res 19, 602-9. 
14. Ziats, N. P., Miller, K. M., and Anderson, J. M. (1988) Biomaterials 9, 5-13. 
15. Brown, A. L., Brook-Allred, T. T., Waddell, J. E., White, J., Werkmeister, J. A., 
Ramshaw, J. A., Bagli, D. J., and Woodhouse, K. A. (2005) Biomaterials 26, 529-43. 
16. Chun, S. Y., Lim, G. J., Kwon, T. G., Kwak, E. K., Kim, B. W., Atala, A., and Yoo, J. J. 
(2007) Biomaterials 28, 4251-6. 
17. Dawson, R. A., Goberdhan, N. J., Freedlander, E., and MacNeil, S. (1996) Burns 22, 93-
100. 
 21
18. Daley, W. P., Peters, S. B., and Larsen, M. (2008) J Cell Sci 121, 255-64. 
19. Aharoni, D., Meiri, I., Atzmon, R., Vlodavsky, I., and Amsterdam, A. (1997) Curr Biol 7, 
43-51. 
20. Hodde, J. (2002) Tissue Eng 8, 295-308. 
21. Santucci, R. A., and Barber, T. D. (2005) Int Braz J Urol 31, 192-203. 
22. Mohamed, F., and van der Walle, C. F. (2008) J Pharm Sci 97, 71-87. 
23. Talja, M., Valimaa, T., Tammela, T., Petas, A., and Tormala, P. (1997) J Endourol 11, 
391-7. 
24. Ashammakhi, N., and Rokkanen, P. (1997) Biomaterials 18, 3-9. 
25. Daniels, A. U., Chang, M. K., and Andriano, K. P. (1990) J Appl Biomater 1, 57-78. 
26. Hutmacher, D. W., Schantz, J. T., Lam, C. X., Tan, K. C., and Lim, T. C. (2007) J Tissue 
Eng Regen Med 1, 245-60. 
27. Ma, Z., Mao, Z., and Gao, C. (2007) Colloids Surf B Biointerfaces 60, 137-57. 
28. Penkala, R. A., and Kim, S. S. (2007) Expert Rev Med Devices 4, 65-72. 
29. Atala, A. (2006) Curr Opin Pediatr 18, 167-71. 
30. De Filippo, R. E., Yoo, J. J., and Atala, A. (2003) Tissue Eng 9, 301-6. 
31. Amiel, G. E., Komura, M., Shapira, O., Yoo, J. J., Yazdani, S., Berry, J., Kaushal, S., 
Bischoff, J., Atala, A., and Soker, S. (2006) Tissue Eng 12, 2355-65. 
32. Lee, S. J., Yoo, J. J., Lim, G. J., Atala, A., and Stitzel, J. (2007) J Biomed Mater Res A 
83, 999-1008. 
33. Bacakova, L., Filova, E., Rypacek, F., Svorcik, V., and Stary, V. (2004) Physiol Res 53 
Suppl 1, S35-45. 
34. Lai, J. Y., Chang, P. Y., and Lin, J. N. (2005) J Pediatr Surg 40, 1869-73. 
 22
 23
35. Lee, S. J., Lim, G. J., Lee, J. W., Atala, A., and Yoo, J. J. (2006) Biomaterials 27, 3466-
72. 
36. Freytes, D. O., Tullius, R. S., Valentin, J. E., Stewart-Akers, A. M., and Badylak, S. F. 
(2008) J Biomed Mater Res A. 
37. Cilento, B. G., Freeman, M. R., Schneck, F. X., Retik, A. B., and Atala, A. (1994) J Urol 
152, 665-70. 
38. Atala, A., Vacanti, J. P., Peters, C. A., Mandell, J., Retik, A. B., and Freeman, M. R. 
(1992) J Urol 148, 658-62. 
39. Freeman, M. R., Yoo, J. J., Raab, G., Soker, S., Adam, R. M., Schneck, F. X., Renshaw, 
A. A., Klagsbrun, M., and Atala, A. (1997) J Clin Invest 99, 1028-36. 
40. Hiles, M. C., Badylak, S. F., Geddes, L. A., Kokini, K., and Morff, R. J. (1993) J Biomed 
Mater Res 27, 139-44. 
 
 
